Stonepine Capital Management, LLC
Bend, OR · CIK 1440771 · 13F filing filed 2023-08-11
SEC-registered investment adviser since 2026 · limited liability company
- Assets managed$181.0m
- Staff4 · 3 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds1 (1 hedge) · $181.0m gross assets
- Websitestonepinecap.com
- Form ADV · 2026-06-26SEC adviser record
- Legal entitySTONEPINE CAPITAL MANAGEMENT, LLC (US)
- Kindhedge funds, futures
- Others nearbyBend, OR, Sausalito, CA
As an employer
- Offices in1 country
- Private fundshedge 2
Where they work
Offices
From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.
| City | People |
|---|---|
| Bend, OR (main office)United States | about 1 |
| Sausalito, CA2 officesUnited States | 2 |
Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.
Holdings, Q2 2023
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| QUIDELORTHO CORP QDEL | $51.3m18.51% | Added +340.3k |
| EVOLUS INC EOLS | $32.8m11.82% | Added +3.9m |
| ADMA BIOLOGICS INC ADMA | $32.4m11.70% | Added +1.1m |
| GALAPAGOS NV LKFT | $27.8m10.01% | Reduced -99.6k |
| AMYLYX PHARMACEUTICALS INC AMLX | $24.2m8.72% | New |
| MAXCYTE INC MXCT | $18.2m6.57% | Added +1.3m |
| XERIS BIOPHARMA HOLDINGS INC XERS | $14.4m5.20% | Reduced -3.1m |
| THIRD HARMONIC BIO INC COM | $13.4m4.85% | Reduced -338.8k |
| ATYR PHARMA INC ATYR | $10.0m3.61% | Reduced -198.5k |
| X4 PHARMACEUTICALS INC COM | $8.9m3.22% | New |
| SCYNEXIS INC COM NEW | $8.7m3.14% | Added +2.5m |
| XOMA ROYALTY CORPORATION XOMA | $6.6m2.38% | Added +31.3k |
| REZOLUTE INC RZLT | $6.1m2.19% | Reduced -15.2k |
| TELA BIO INC TELA | $4.9m1.76% | New |
| UROGEN PHARMA LTD URGN | $4.6m1.67% | Reduced -253.0k |
| EXAGEN INC XGN | $3.0m1.10% | Added +12.3k |
| GAMIDA CELL LTD SHS | $2.9m1.04% | New |
| ATEA PHARMACEUTICALS INC AVIR | $2.8m1.01% | Added +67.6k |
| DELCATH SYS INC DCTH | $2.1m0.76% | New |
| CASTLE BIOSCIENCES INC CSTL | $1.3m0.46% | Reduced -200.9k |
| AYTU BIOPHARMA INC AYTU | $755.8k0.27% | New |
Sold out since Q1 2023
| Security | Value then |
|---|---|
| AMRYT PHARMA PLC | $91.5m6.3m shares |
| CTI BIOPHARMA CORP | $27.4m6.5m shares |
| DYNAVAX TECHNOLOGIES CORP DVAX | $4.1m416.5k shares |
| APOLLO ENDOSURGERY INC | $3.7m370.0k shares |
| TRAVERE THERAPEUTICS INC TVTX | $3.0m132.0k shares |
| CONFORMIS INC CFMS | $648.3k402.7k shares |
| CIDARA THERAPEUTICS INC | $1.3k1.0k shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| QUOIN PHARMACEUTICALS LTD QNRX · 13G · filed 2026-05-15 | 10.0% |
| AEON BIOPHARMA INC AEON · 13G · filed 2026-07-21 | 9.9%≈ $3.9m |
| AZITRA INC 13G · filed 2026-06-22 | 9.9% |
| ELOXX PHARMACEUTICALS INC ELOX · 13G · filed 2026-06-16 | 9.9%≈ $5.6m |
| SINTX TECHNOLOGIES INC SINT · 13G · filed 2026-06-09 | 9.9%≈ $1.2m |
| CNS PHARMACEUTICALS INC CNSP · 13G · filed 2026-05-15 | 9.9%≈ $760.7k |
| CELLECTAR BIOSCIENCES INC CLRB · 13G · filed 2026-05-11 | 9.9%≈ $2.4m |
| CURIS INC 13G · filed 2026-03-27 | 9.9%≈ $2.1m |
| IN8BIO INC INAB · 13G · filed 2025-12-22 | 9.9%≈ $1.4m |
| AYTU BIOPHARMA INC AYTU · 13G · filed 2025-08-13 | 9.9%≈ $1.9m |
| OPTINOSE INC OPTN · 13G · filed 2025-05-14 | 7.8% |
| FEMASYS INC FEMY · 13G · filed 2026-08-31 | 7.2%≈ $2.6m |
| EDESA BIOTECH INC EDSA · 13G · filed 2026-08-26 | 6.9%≈ $5.9m |
| CALCIMEDICA INC 13G · filed 2026-08-25 | 6.0%≈ $2.2m |
| TELA BIO INC TELA · 13G · filed 2025-02-13 | 6.0%≈ $1.8m |
| PASITHEA THERAPEUTICS CORP KTTA · 13G · filed 2026-06-23 | 5.8%≈ $1.0m |